Элранатамаб
ElranatamabМНН
Rec. INN (наименование, зарегистрированное ВОЗ)
АТХ
Фармакологическая группа
Категория при беременности по FDA
N (не классифицировано FDA)
CAS
2408850-14-4
Химическое название
immunoglobulin G2-kappa, anti-[Homo sapiens TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)] and anti- [Homo sapiens CD3E (CD3e molecule, Leu-4)], Homo sapiens and humanized monoclonal antibody, bispecific;
gamma2 heavy chain Homo sapiens anti-TNFRSF17 (1- 441) [VH anti-TNFRSF17 (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ1*01(100%), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -Homo sapiens IGHG2*01, G2m.. CH2 V45.1 (CH1 (116-213), hinge 1-12 C5>E (218), P10>E (223) (214-225), CH2 D27>A (259), V45.1 (276), A115>S (324), P116>S (325) (226-334), CH3 L24>E(362),(335-439), CHS (440-441)) (116-441)], (129-215')- disulfide with kappa light chain Homo sapiens anti- TNFRSF17 (1'-215') [V-KAPPA anti-TNFRSF17 (Homo sapiens IGKV3-20*01 (94.8%) -IGKJ1*01 (100%), CDR- IMGT [7.3.9] (27-33.51-53.90-98)) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; gamma2 heavy chain humanized anti-CD3E (1''-447'') [VH anti-CD3E (Homo sapiens IGHV3-48*03 (84.0%) -(IGHD) - IGHJ4*01(85.7%) L123>T (116''), CDR-IMGT [8.10.12] (26-33.51-60.99-110)) (1''-121'') -Homo sapiens IGHG2*01, G2m.. CH2 V45.1 (CH1 (122''-219''), hinge 1-12 C5>R (224''), E7>R (226''), P10>R (229'') (220''-231''), CH2 D27>A (265''), V45.1 (282''), A115>S (330''), P116>S (331'') (232''-340''), CH3K88>R (409'') (341''-445''), CHS (446''-447'')) (122''-447'')], (135''-219''')-disulfide with kappa light chain humanized anti-CD3E (1'''-219''') [V-KAPPA anti- CD3E (Homo sapiens IGKV4-1*01 (89.8%) -IGKJ2*02 (90.9%) Q120>S (105), CDR-IMGT [12.3.8] (27-38.56-58.95-102)) (1'''-112''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dimer (217- 223'':221-227'':224-230'')-trisdisulfide, produced in a Chinese hamster ovary (CHO)-K1SV cell line, glycoform alfa
gamma2 heavy chain Homo sapiens anti-TNFRSF17 (1- 441) [VH anti-TNFRSF17 (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ1*01(100%), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -Homo sapiens IGHG2*01, G2m.. CH2 V45.1 (CH1 (116-213), hinge 1-12 C5>E (218), P10>E (223) (214-225), CH2 D27>A (259), V45.1 (276), A115>S (324), P116>S (325) (226-334), CH3 L24>E(362),(335-439), CHS (440-441)) (116-441)], (129-215')- disulfide with kappa light chain Homo sapiens anti- TNFRSF17 (1'-215') [V-KAPPA anti-TNFRSF17 (Homo sapiens IGKV3-20*01 (94.8%) -IGKJ1*01 (100%), CDR- IMGT [7.3.9] (27-33.51-53.90-98)) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; gamma2 heavy chain humanized anti-CD3E (1''-447'') [VH anti-CD3E (Homo sapiens IGHV3-48*03 (84.0%) -(IGHD) - IGHJ4*01(85.7%) L123>T (116''), CDR-IMGT [8.10.12] (26-33.51-60.99-110)) (1''-121'') -Homo sapiens IGHG2*01, G2m.. CH2 V45.1 (CH1 (122''-219''), hinge 1-12 C5>R (224''), E7>R (226''), P10>R (229'') (220''-231''), CH2 D27>A (265''), V45.1 (282''), A115>S (330''), P116>S (331'') (232''-340''), CH3K88>R (409'') (341''-445''), CHS (446''-447'')) (122''-447'')], (135''-219''')-disulfide with kappa light chain humanized anti-CD3E (1'''-219''') [V-KAPPA anti- CD3E (Homo sapiens IGKV4-1*01 (89.8%) -IGKJ2*02 (90.9%) Q120>S (105), CDR-IMGT [12.3.8] (27-38.56-58.95-102)) (1'''-112''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dimer (217- 223'':221-227'':224-230'')-trisdisulfide, produced in a Chinese hamster ovary (CHO)-K1SV cell line, glycoform alfa
Структура
Иностранные названия
- Elranatamabum (латинское)
- Elranatamab (английское)
- Elranatamab (немецкое)
- Elranatamab (французское)
- Elranatamab (испанское)
Подробнее по теме
Узнайте дополнительные сведения о действующем веществе Элранатамаб: